BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi WM, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021;19:246-258.e9. [PMID: 32407970 DOI: 10.1016/j.cgh.2020.05.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Yuan BH, Zhu YK, Li RH. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With CHB: A Comment for Moving Forward. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00278-0. [PMID: 33716140 DOI: 10.1016/j.cgh.2021.03.014] [Reference Citation Analysis]
2 Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. J Hepatol 2021:S0168-8278(21)02087-0. [PMID: 34606915 DOI: 10.1016/j.jhep.2021.09.025] [Reference Citation Analysis]
3 Harputluoglu M, Carr BI. Hepatitis B Before and After Hepatocellular Carcinoma. J Gastrointest Cancer 2021. [PMID: 34762265 DOI: 10.1007/s12029-021-00745-4] [Reference Citation Analysis]
4 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
6 Na JE, Sinn DH, Lee JH, Jang HJ, Baek SY, Kim KA, Kang WS, Gwak GY, Paik YH, Kim YJ, Choi MS, Yoon JH, Lee JH, Koh KC, Paik SW. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J Viral Hepat 2021. [PMID: 34251707 DOI: 10.1111/jvh.13572] [Reference Citation Analysis]
7 Qi W, Shen J, Dai J, Wu Y, Zhang Y, Leng S, Gao F, Ran S, Peng W, Zhang X, Wen T, Li C. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study. Cancer Med 2021. [PMID: 34643050 DOI: 10.1002/cam4.4348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Zhu DM, Xie J, Ye CY, Qian MY, Xue Y. Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy. Can J Gastroenterol Hepatol 2020;2020:8871024. [PMID: 33381476 DOI: 10.1155/2020/8871024] [Reference Citation Analysis]
9 Yip TC, Lai JC, Wong GL. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol 2020;55:1023-36. [PMID: 32974760 DOI: 10.1007/s00535-020-01726-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Choi WM, Choi J, Lim YS. Reply. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00345-1. [PMID: 33798710 DOI: 10.1016/j.cgh.2021.03.035] [Reference Citation Analysis]
11 Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY) 2021;13:7147-65. [PMID: 33658397 DOI: 10.18632/aging.202573] [Reference Citation Analysis]
12 Yang L, Bi L, Jin L, Wang Y, Li Y, Li Z, He W, Cui H, Miao J, Wang L. Geniposide Ameliorates Liver Fibrosis Through Reducing Oxidative Stress and Inflammatory Respose, Inhibiting Apoptosis and Modulating Overall Metabolism. Front Pharmacol 2021;12:772635. [PMID: 34899328 DOI: 10.3389/fphar.2021.772635] [Reference Citation Analysis]
13 Choi J, Lim YS. Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. Kaohsiung J Med Sci 2021;37:262-7. [PMID: 33502828 DOI: 10.1002/kjm2.12364] [Reference Citation Analysis]
14 Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402-12. [PMID: 34157830 DOI: 10.3350/cmh.2021.0179] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Wang SH, Yeh SH, Chen PJ. Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers (Basel) 2021;13:2454. [PMID: 34070067 DOI: 10.3390/cancers13102454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 González Grande R, Santaella Leiva I, López Ortega S, Jiménez Pérez M. Present and future management of viral hepatitis. World J Gastroenterol 2021; 27(47): 8081-8102 [DOI: 10.3748/wjg.v27.i47.8081] [Reference Citation Analysis]
17 Arslan F, Franci G, Maria Nastri B, Pagliano P. Hepatitis B virus-induced hepatocarcinogenesis: A virological and oncological perspective. J Viral Hepat 2021;28:1104-9. [PMID: 34003561 DOI: 10.1111/jvh.13551] [Reference Citation Analysis]
18 Choi J, Lim YS. REPLY. Hepatology 2021;73:467. [PMID: 32598515 DOI: 10.1002/hep.31438] [Reference Citation Analysis]
19 Lee J, Cho S, Kim HJ, Lee H, Ko MJ, Lim YS. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study. J Viral Hepat 2021;28:353-63. [PMID: 33051945 DOI: 10.1111/jvh.13418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Reference Citation Analysis]